Invega sustenna patent expiration date?

What is the current status of Invega Sustenna's patent?

Invega Sustenna, a long-acting injectable antipsychotic medication, is an off-patent product. [1] Its active ingredient, paliperidone, is a key component of Invega Sustenna. In August 2011, the patent for long-acting paliperidone formulations, which include Invega Sustenna, was granted to Janssen Pharmaceuticals, a company owned by Johnson & Johnson, in the US. [2][3]

When did the patent for Invega Sustenna expire?

The US patent for Invega Sustenna expired on 26 August 2021, according to the United States Patent and Trademark Office (USPTO). However, this does not automatically mean that generic versions are available in the market.

Are generic versions of Invega Sustenna available now?

Since the patent for Invega Sustenna has expired, generic manufacturers can produce and market their versions of this medication. Generic versions of Invega Sustenna are indeed commercially available in the US. [4]

References:

[1] DrugPatentWatch.com: Paliperidone Patents

[2] US Patent No. US 7943416 B2: Paliperidone, its manufacture, use, composition, formulation or production

[3] US Patent No. US 7943416 B2: Patent Expiration Date

[4] DrugPatentWatch.com: Generic Paliperidone (Invega) Availability